Bicara Therapeutics
BCAX
146 hedge funds and large institutions have $1.4B invested in Bicara Therapeutics in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 40 reducing their positions, and 21 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 40
39% more capital invested
Capital invested by funds: $1.01B → $1.4B (+$390M)
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
23.56% more ownership
Funds ownership: 106.52% → 130.08% (+24%)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4% more funds holding
Funds holding: 141 → 146 (+5)
62% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$58M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$31.8M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$24.9M |
| 4 |
RPSM
Royalty Pharma Sub-Manager
New York
|
+$19.4M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.5M |
| 2 |
Millennium Management
New York
|
-$4.79M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.96M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.16M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.68M |
BCAX Hedge Fund Activity: Q1 2026 in Review
146 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q1 2026, worth a combined $1.4B — up 39% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BCAX positions and 21 closed out — a net gain of 8 holders — while 58 added to existing stakes and 40 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $58M. The largest seller was Fidelity Investments, cutting an estimated $21.5M.
- 146 institutional investors held Bicara Therapeutics (BCAX) as of Q1 2026, up from 141 in Q4 2025.
- Funds reported $1.4B of Bicara Therapeutics stock for Q1 2026, up 39% quarter-over-quarter.
- 29 funds opened new Bicara Therapeutics positions in Q1 2026 and 21 closed out, a net change of +8 holders.
- The largest Bicara Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $58M added.
- The largest Bicara Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $21.5M sold.
Based on aggregated 13F filings for Q1 2026.